Arcus Biosciences (RCUS) Competitors $13.34 -0.03 (-0.19%) Closing price 10/3/2025 03:59 PM EasternExtended Trading$13.67 +0.32 (+2.44%) As of 10/3/2025 05:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RCUS vs. MRUS, TGTX, MENS, PTCT, KRYS, ACLX, ARWR, PCVX, ACAD, and PTGXShould you be buying Arcus Biosciences stock or one of its competitors? The main competitors of Arcus Biosciences include Merus (MRUS), TG Therapeutics (TGTX), Jyong Biotech (MENS), PTC Therapeutics (PTCT), Krystal Biotech (KRYS), Arcellx (ACLX), Arrowhead Pharmaceuticals (ARWR), Vaxcyte (PCVX), ACADIA Pharmaceuticals (ACAD), and Protagonist Therapeutics (PTGX). These companies are all part of the "pharmaceutical products" industry. Arcus Biosciences vs. Its Competitors Merus TG Therapeutics Jyong Biotech PTC Therapeutics Krystal Biotech Arcellx Arrowhead Pharmaceuticals Vaxcyte ACADIA Pharmaceuticals Protagonist Therapeutics Arcus Biosciences (NYSE:RCUS) and Merus (NASDAQ:MRUS) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, analyst recommendations, dividends, institutional ownership and risk. Do analysts rate RCUS or MRUS? Arcus Biosciences currently has a consensus target price of $21.14, indicating a potential upside of 58.43%. Merus has a consensus target price of $92.88, indicating a potential downside of 1.50%. Given Arcus Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Arcus Biosciences is more favorable than Merus.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arcus Biosciences 1 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.50Merus 1 Sell rating(s) 12 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.18 Does the media prefer RCUS or MRUS? In the previous week, Merus had 56 more articles in the media than Arcus Biosciences. MarketBeat recorded 60 mentions for Merus and 4 mentions for Arcus Biosciences. Arcus Biosciences' average media sentiment score of 0.61 beat Merus' score of 0.24 indicating that Arcus Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcus Biosciences 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Merus 10 Very Positive mention(s) 9 Positive mention(s) 24 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral Which has more risk and volatility, RCUS or MRUS? Arcus Biosciences has a beta of 0.77, suggesting that its share price is 23% less volatile than the S&P 500. Comparatively, Merus has a beta of 1.26, suggesting that its share price is 26% more volatile than the S&P 500. Which has better valuation and earnings, RCUS or MRUS? Merus has lower revenue, but higher earnings than Arcus Biosciences. Merus is trading at a lower price-to-earnings ratio than Arcus Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArcus Biosciences$262M5.42-$283M-$3.17-4.21Merus$36.13M197.37-$215.33M-$5.50-17.14 Is RCUS or MRUS more profitable? Arcus Biosciences has a net margin of -109.56% compared to Merus' net margin of -685.64%. Merus' return on equity of -50.28% beat Arcus Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Arcus Biosciences-109.56% -55.96% -25.73% Merus -685.64%-50.28%-42.00% Do insiders & institutionals believe in RCUS or MRUS? 92.9% of Arcus Biosciences shares are owned by institutional investors. Comparatively, 96.1% of Merus shares are owned by institutional investors. 9.6% of Arcus Biosciences shares are owned by insiders. Comparatively, 3.7% of Merus shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. SummaryArcus Biosciences beats Merus on 10 of the 16 factors compared between the two stocks. Get Arcus Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for RCUS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RCUS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RCUS vs. The Competition Export to ExcelMetricArcus BiosciencesMED IndustryMedical SectorNYSE ExchangeMarket Cap$1.42B$3.33B$6.08B$21.63BDividend YieldN/A2.27%5.68%3.56%P/E Ratio-4.2122.1478.0529.82Price / Sales5.42416.32577.1494.31Price / CashN/A47.2037.7924.73Price / Book2.529.9312.554.61Net Income-$283M-$52.80M$3.31B$1.00B7 Day Performance4.05%5.22%4.28%2.07%1 Month Performance15.33%13.01%7.85%3.89%1 Year Performance-19.85%25.18%71.37%13.14% Arcus Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RCUSArcus Biosciences1.8001 of 5 stars$13.35-0.2%$21.14+58.4%-12.8%$1.42B$262M-4.21500MRUSMerus1.0127 of 5 stars$69.19+1.4%$90.54+30.9%+89.1%$5.16B$36.13M-12.5837Trending NewsAnalyst DowngradeOptions VolumeAnalyst RevisionTGTXTG Therapeutics4.0007 of 5 stars$34.97+8.0%$48.00+37.3%+65.4%$5.14B$329M94.51290MENSJyong BiotechN/A$59.53-9.3%N/AN/A$4.99BN/A0.0031High Trading VolumePTCTPTC Therapeutics3.4276 of 5 stars$60.85+0.6%$69.00+13.4%+84.8%$4.80B$806.78M8.731,410KRYSKrystal Biotech4.6767 of 5 stars$165.42+1.1%$209.00+26.3%+4.2%$4.73B$290.52M33.62210Positive NewsACLXArcellx2.2298 of 5 stars$78.22+0.5%$114.31+46.1%+11.6%$4.32B$107.94M-22.8780Insider TradeARWRArrowhead Pharmaceuticals4.1734 of 5 stars$32.05+4.4%$43.14+34.6%+91.6%$4.24B$3.55M-25.04400Positive NewsInsider TradePCVXVaxcyte2.4804 of 5 stars$33.47+5.4%$106.25+217.4%-61.6%$4.12BN/A-8.14160Positive NewsACADACADIA Pharmaceuticals4.4726 of 5 stars$24.53+0.5%$29.65+20.9%+48.1%$4.12B$957.80M18.44510PTGXProtagonist Therapeutics2.167 of 5 stars$64.51+3.7%$68.08+5.5%+46.2%$3.87B$434.43M92.16120Positive News Related Companies and Tools Related Companies Merus Competitors TG Therapeutics Competitors Jyong Biotech Competitors PTC Therapeutics Competitors Krystal Biotech Competitors Arcellx Competitors Arrowhead Pharmaceuticals Competitors Vaxcyte Competitors ACADIA Pharmaceuticals Competitors Protagonist Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:RCUS) was last updated on 10/4/2025 by MarketBeat.com Staff From Our PartnersNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredURGENT: The Market's 3 Red Flags Are FlashingThe warning signs that preceded the 2008 crash are reappearing: an irrational NASDAQ bubble, a record-high gol...StockEarnings | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredIs Nvidia about to Trigger Another 150X Opportunity?Nvidia gave investors a chance to make more than 150 times their money with its AI chips, known as graphics pr...InvestorPlace | SponsoredLost Decade warning – do this nowWith the Magnificent 7 trading at bubble-like valuations, another “Lost Decade” could be looming — but Porter ...Porter & Company | SponsoredUrgent: $3,452.50 a Month in Passive "AI Equity Checks"The U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcus Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arcus Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RCUS Stock Alerts